Immunicum AB (publ) today announced that it has received Advanced Therapy Medicinal Product (ATMP) classification from the European Medicines Agency (EMA) for the Company’s lead cancer relapse vaccine ...
MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...
- A New Treatment Which Offers Hope to Patients Suffering From Thromboangiitis Obliterans (Buerger's Disease) Affecting an Estimated 2 out of Every 10,000 People in Europe - The First Real Hope for ...
Ocugen, Inc. has announced that the European Commission has given a positive opinion for the classification of its gene therapy product, OCU400, as an Advanced Therapy Medicinal Product (ATMP) by the ...
Advanced Therapy Medicinal Product classification for Ixaka Ltd’s chemically encapsulated lentiviral vector Advanced Therapy Medicinal Product classification for Ixaka Ltd’s chemically encapsulated ...
MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that ...
Genome editing technologies such as CRISPR–Cas9 are being developed as therapeutic platforms, especially for monogenic diseases that could be treated by targeting the associated mutations. The first ...
MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback